Search Results

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease

Voltron Therapeutics, Inc announced that it has signed a new Sponsored Research Agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.

DIMERx, Inc., an advance-stage biopharmaceutical company, announced that it has secured rights from Massachusetts General Hospital for a novel amino acid dimer to be developed for two rare disease indications in the U.S. and as a proprietary medical food for ex-U.S. markets.

Asensus Surgical, Inc. announced that St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System in the Urology and Gastroenterology/General Surgery department.

Sermonix Pharmaceuticals Inc. today announced it will host a virtual KOL fireside chat on Monday, April 22, 2024 from noon to 1 p.m. ET, featuring Senthil Damodaran, M.D., Ph.D. (MD Anderson Cancer Center) and Seth Wander, M.D., Ph.D. (Harvard Medical School, Massachusetts General Hospital) to discuss the unmet need and current treatment landscape for metastatic breast cancer.

Derm-Biome Pharmaceuticals Inc is excited to announce that it is collaborating with Dr. Anna Mandinova from the Department of Dermatology at Massachusetts General Hospital in a skin cancer study.